Valuation Update With 7 Day Price Move • Apr 28
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹7.68, the stock trades at a trailing P/E ratio of 9.9x. Average trailing P/E is 40x in the Healthcare industry in India. Total loss to shareholders of 46% over the past three years. Valuation Update With 7 Day Price Move • Mar 30
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to ₹8.02, the stock trades at a trailing P/E ratio of 10.3x. Average trailing P/E is 33x in the Healthcare industry in India. Total loss to shareholders of 29% over the past three years. Valuation Update With 7 Day Price Move • Feb 18
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹10.74, the stock trades at a trailing P/E ratio of 13.8x. Average trailing P/E is 38x in the Healthcare industry in India. Total loss to shareholders of 14% over the past three years. Valuation Update With 7 Day Price Move • Feb 03
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to ₹14.39, the stock trades at a trailing P/E ratio of 18.5x. Average trailing P/E is 36x in the Healthcare industry in India. Negligible returns to shareholders over past three years. Valuation Update With 7 Day Price Move • Jan 09
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to ₹13.50, the stock trades at a trailing P/E ratio of 17.3x. Average trailing P/E is 41x in the Healthcare industry in India. Total loss to shareholders of 18% over the past three years. Valuation Update With 7 Day Price Move • Dec 23
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹16.59, the stock trades at a trailing P/E ratio of 21.3x. Average trailing P/E is 41x in the Healthcare industry in India. Total returns to shareholders of 3.0% over the past three years. Reported Earnings • Nov 28
First half 2026 earnings released: EPS: ₹0.59 (vs ₹0.14 in 1H 2025) First half 2026 results: EPS: ₹0.59 (up from ₹0.14 in 1H 2025). Revenue: ₹723.3m (down 20% from 1H 2025). Net income: ₹14.1m (up 319% from 1H 2025). Profit margin: 2.0% (up from 0.4% in 1H 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. New Risk • Nov 27
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.9% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.6x net interest cover). Share price has been highly volatile over the past 3 months (8.9% average weekly change). High level of non-cash earnings (21% accrual ratio). Market cap is less than US$10m (₹383.0m market cap, or US$4.29m). Valuation Update With 7 Day Price Move • Nov 20
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to ₹15.51, the stock trades at a trailing P/E ratio of 38.3x. Average trailing P/E is 42x in the Healthcare industry in India. Total loss to shareholders of 5.6% over the past three years. Announcement • Nov 11
Dipna Pharmachem Limited to Report First Half, 2026 Results on Nov 14, 2025 Dipna Pharmachem Limited announced that they will report first half, 2026 results on Nov 14, 2025 Valuation Update With 7 Day Price Move • Oct 20
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹20.37, the stock trades at a trailing P/E ratio of 50.3x. Average trailing P/E is 45x in the Healthcare industry in India. Total returns to shareholders of 19% over the past three years. New Risk • Sep 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.6x net interest cover). High level of non-cash earnings (21% accrual ratio). Market cap is less than US$10m (₹502.5m market cap, or US$5.71m). Minor Risk Share price has been volatile over the past 3 months (6.6% average weekly change). Announcement • Aug 28
Dipna Pharmachem Limited announced a financing transaction Dipna Pharmachem Limited announced a private placement to issue Equity shares on August 28, 2025. Announcement • Aug 11
Dipna Pharmachem Limited, Annual General Meeting, Aug 30, 2025 Dipna Pharmachem Limited, Annual General Meeting, Aug 30, 2025, at 16:00 Indian Standard Time. Reported Earnings • Jul 08
Full year 2025 earnings released: EPS: ₹0.41 (vs ₹0.90 in FY 2024) Full year 2025 results: EPS: ₹0.41 (down from ₹0.90 in FY 2024). Revenue: ₹1.25b (down 24% from FY 2024). Net income: ₹9.74m (down 10% from FY 2024). Profit margin: 0.8% (up from 0.7% in FY 2024). The increase in margin was driven by lower expenses. Announcement • Jul 02
Dipna Pharmachem Limited to Report Second Half, 2025 Results on Jul 07, 2025 Dipna Pharmachem Limited announced that they will report second half, 2025 results on Jul 07, 2025 New Risk • Jun 29
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.6x net interest cover). High level of non-cash earnings (25% accrual ratio). Market cap is less than US$10m (₹555.2m market cap, or US$6.49m). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Profit margins are more than 30% lower than last year (0.5% net profit margin). Valuation Update With 7 Day Price Move • May 16
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹25.06, the stock trades at a trailing P/E ratio of 72.5x. Average trailing P/E is 40x in the Healthcare industry in India. Total returns to shareholders of 183% over the past year. Valuation Update With 7 Day Price Move • Apr 29
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to ₹21.42, the stock trades at a trailing P/E ratio of 61.9x. Average trailing P/E is 39x in the Healthcare industry in India. Total returns to shareholders of 137% over the past year. Announcement • Mar 14
Dipna Pharmachem Limited announced that it expects to receive INR 249.923813 million in funding Dipna Pharmachem Limited announced a private placement of up to 76,605,000 convertible warrants at a price of INR 3.2625 per warrant for the gross proceeds of INR 249,923,812.5 on March 13, 2025. The warrants will be convertible at an exercise price of INR 9.7875. The transaction will include participation from Keyur Dipakkumar Shah for 1,08,78,000 warrants, Dipna Keyur Shah for 1,08,78,000 warrants, Bindesh Manharlal Doshi for 363,000 warrants, Jimit Bindesh Doshi for 360,000 warrants, Keneel Ajay Shah for 159,000 warrants and other investors. The transaction has been approved by the shareholders of the company. Valuation Update With 7 Day Price Move • Feb 06
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹15.90, the stock trades at a trailing P/E ratio of 46x. Average trailing P/E is 44x in the Healthcare industry in India. Total returns to shareholders of 40% over the past year. Valuation Update With 7 Day Price Move • Dec 24
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹9.03, the stock trades at a trailing P/E ratio of 26.1x. Average trailing P/E is 43x in the Healthcare industry in India. Total returns to shareholders of 9.9% over the past year. Reported Earnings • Dec 13
First half 2025 earnings released: EPS: ₹0.14 (vs ₹0.49 in 1H 2024) First half 2025 results: EPS: ₹0.14 (down from ₹0.49 in 1H 2024). Revenue: ₹906.2m (up 22% from 1H 2024). Net income: ₹3.37m (down 43% from 1H 2024). Profit margin: 0.4% (down from 0.8% in 1H 2024). The decrease in margin was driven by higher expenses. New Risk • Dec 12
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 1.5x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.5x net interest cover). High level of non-cash earnings (25% accrual ratio). Shareholders have been substantially diluted in the past year (101% increase in shares outstanding). Market cap is less than US$10m (₹181.5m market cap, or US$2.14m). Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Profit margins are more than 30% lower than last year (0.5% net profit margin). Valuation Update With 7 Day Price Move • Dec 04
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹8.07, the stock trades at a trailing P/E ratio of 17.9x. Average trailing P/E is 46x in the Healthcare industry in India. Total loss to shareholders of 8.3% over the past year. New Risk • Nov 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (101% increase in shares outstanding). Market cap is less than US$10m (₹160.6m market cap, or US$1.90m). Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change). Announcement • Aug 28
Dipna Pharmachem Limited announced a financing transaction Dipna Pharmachem Limited announced a private placement to issue Warrants, convertible into Equity shares on a preferential basis on August 27, 2024. The company announced it has obtained board approval from board of directors in 13th Annual General Meeting of the Company. Valuation Update With 7 Day Price Move • Aug 22
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₹8.66, the stock trades at a trailing P/E ratio of 19.2x. Average trailing P/E is 51x in the Healthcare industry in India. Total loss to shareholders of 39% over the past year. Reported Earnings • Aug 07
Full year 2024 earnings released: EPS: ₹0.90 (vs ₹0.76 in FY 2023) Full year 2024 results: EPS: ₹0.90 (up from ₹0.76 in FY 2023). Revenue: ₹1.64b (up 65% from FY 2023). Net income: ₹10.9m (up 19% from FY 2023). Profit margin: 0.7% (down from 0.9% in FY 2023). The decrease in margin was driven by higher expenses. Announcement • Jul 30
Dipna Pharmachem Limited, Annual General Meeting, Aug 27, 2024 Dipna Pharmachem Limited, Annual General Meeting, Aug 27, 2024, at 16:00 Indian Standard Time. Reported Earnings • Jun 18
Full year 2024 earnings released: EPS: ₹0.90 (vs ₹0.76 in FY 2023) Full year 2024 results: EPS: ₹0.90 (up from ₹0.76 in FY 2023). Revenue: ₹1.64b (up 65% from FY 2023). Net income: ₹10.9m (up 19% from FY 2023). Profit margin: 0.7% (down from 0.9% in FY 2023). The decrease in margin was driven by higher expenses. Announcement • Jun 13
Dipna Pharmachem Limited to Report Q4, 2024 Results on Jun 12, 2024 Dipna Pharmachem Limited announced that they will report Q4, 2024 results on Jun 12, 2024 New Risk • May 05
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.1x net interest cover). Share price has been highly volatile over the past 3 months (12% average weekly change). High level of non-cash earnings (84% accrual ratio). Shareholders have been substantially diluted in the past year (101% increase in shares outstanding). Market cap is less than US$10m (₹217.8m market cap, or US$2.61m). Minor Risk Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Announcement • Apr 26
Dipna Pharmachem Limited announced a financing transaction Dipna Pharmachem Limited announced a private placement to issue common shares or warrants on April 25, 2024. The transaction has been approved by the shareholders of the company. The transaction is subject to general shareholders which is to be held on May 2, 2024. Valuation Update With 7 Day Price Move • Apr 17
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to ₹8.02, the stock trades at a trailing P/E ratio of 16.5x. Average trailing P/E is 39x in the Healthcare industry in India. Total loss to shareholders of 26% over the past year. New Risk • Mar 31
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 101% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.1x net interest cover). Share price has been highly volatile over the past 3 months (11% average weekly change). High level of non-cash earnings (84% accrual ratio). Shareholders have been substantially diluted in the past year (101% increase in shares outstanding). Market cap is less than US$10m (₹226.5m market cap, or US$2.72m). Valuation Update With 7 Day Price Move • Mar 28
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹9.42, the stock trades at a trailing P/E ratio of 9.6x. Average trailing P/E is 38x in the Healthcare industry in India. Total returns to shareholders of 16% over the past year. Valuation Update With 7 Day Price Move • Feb 28
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹11.23, the stock trades at a trailing P/E ratio of 11.5x. Average trailing P/E is 45x in the Healthcare industry in India. Total returns to shareholders of 15% over the past year. Valuation Update With 7 Day Price Move • Feb 05
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹14.02, the stock trades at a trailing P/E ratio of 14.3x. Average trailing P/E is 50x in the Healthcare industry in India. Total loss to shareholders of 20% over the past year. Announcement • Jan 21
Dipna Pharmachem Limited Announces Resignation of Chinu Kalal as Non-Executive Independent Director Dipna Pharmachem Limited announced that Ms. Chinu Kalal (DIN: 09568622) has resigned as a Non-Executive Independent Director of the Company with effect from 31st January, 2023. Valuation Update With 7 Day Price Move • Jan 09
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹13.02, the stock trades at a trailing P/E ratio of 13.3x. Average trailing P/E is 41x in the Healthcare industry in India. Total loss to shareholders of 37% over the past year. Announcement • Dec 15
Dipna Pharmachem Limited Announces Appointment of Madhuri Gurwani as Company Secretary and Compliance Officer Dipna Pharmachem Limited at its board meeting held on 15th December, 2023, considered and approved Appointment of Ms. Madhuri Gurwani as Company secretary and Compliance Officer of the Company effective 15th December, 2023. Ms. Madhuri Gurwani is Associate Member of the ICSI. A Company Secretary with 9 plus years of experience in handling Secretarial and Legal Compliance of Company with respect to Companies Act, SEBI Regulations, RBI Regulations, Registration of Trademark and Patent. Reported Earnings • Oct 24
First half 2024 earnings released: EPS: ₹0.49 (vs ₹0.28 in 1H 2023) First half 2024 results: EPS: ₹0.49 (up from ₹0.28 in 1H 2023). Revenue: ₹740.3m (up 52% from 1H 2023). Net income: ₹5.90m (up 78% from 1H 2023). Profit margin: 0.8% (up from 0.7% in 1H 2023). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Oct 13
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹17.37, the stock trades at a trailing P/E ratio of 22.8x. Average trailing P/E is 45x in the Healthcare industry in India. Total loss to shareholders of 26% over the past year. Announcement • Oct 06
Dipna Pharmachem Limited to Report First Half, 2024 Results on Oct 11, 2023 Dipna Pharmachem Limited announced that they will report first half, 2024 results on Oct 11, 2023 Valuation Update With 7 Day Price Move • Sep 22
Investor sentiment deteriorates as stock falls 37% After last week's 37% share price decline to ₹16.13, the stock trades at a trailing P/E ratio of 21.2x. Average trailing P/E is 44x in the Healthcare industry in India. Total loss to shareholders of 38% over the past year. Valuation Update With 7 Day Price Move • Sep 08
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹25.65, the stock trades at a trailing P/E ratio of 33.7x. Average trailing P/E is 45x in the Healthcare industry in India. Total loss to shareholders of 19% over the past year. Announcement • Sep 08
Dipna Pharmachem Limited, Annual General Meeting, Sep 29, 2023 Dipna Pharmachem Limited, Annual General Meeting, Sep 29, 2023, at 16:00 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Financial Statements of the Company for the financial year ended on 31st March, 2023 and Statement of Profit and Loss together with the notes forming part thereof and Cash Flow Statement for the financial year ended on that date, and the reports of the Board of Directors ("The Board") and Auditors thereon; to appoint Ms. Dipna Shah , who retires by rotation and being eligible, offers herself for re-appointment; to appoint M/s. Devadiya & Associates, Chartered Accountants, (FRN: 133045W), Ahmedabad, as the Statutory Auditor of the Company; and to consider other matters. Announcement • Aug 22
Dipna Pharmachem Limited Announces Resignation of Ms. Khushboo Jethaliya as Company Secretary / Compliance Officer Dipna Pharmachem Limited announced that Ms. Khushboo Jethaliya, has resigned from the position of the Company Secretary of the Company with effect from 21st August, 2023. New Risk • Jul 11
New major risk - Financial position The company's interest payments are not well covered by earnings. Net interest cover: 2.4x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.4x net interest cover). Share price has been highly volatile over the past 3 months (15% average weekly change). High level of non-cash earnings (95% accrual ratio). Market cap is less than US$10m (₹275.9m market cap, or US$3.35m). Minor Risk Profit margins are more than 30% lower than last year (0.9% net profit margin). Reported Earnings • Jul 11
Full year 2023 earnings released: EPS: ₹261 (vs ₹69.46 in FY 2022) Full year 2023 results: EPS: ₹261. Revenue: ₹999.3m (up 37% from FY 2022). Net income: ₹9.12m (down 22% from FY 2022). Profit margin: 0.9% (down from 1.6% in FY 2022). The decrease in margin was driven by higher expenses. Valuation Update With 7 Day Price Move • Jun 15
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to ₹21.66, the stock trades at a trailing P/E ratio of 22.1x. Average trailing P/E is 38x in the Healthcare industry in India. Valuation Update With 7 Day Price Move • May 26
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹17.40, the stock trades at a trailing P/E ratio of 17.7x. Average trailing P/E is 38x in the Healthcare industry in India. Announcement • May 25
Dipna Pharmachem Limited to Report Second Half, 2023 Results on May 30, 2023 Dipna Pharmachem Limited announced that they will report second half, 2023 results on May 30, 2023 Valuation Update With 7 Day Price Move • Apr 04
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₹13.80, the stock trades at a trailing P/E ratio of 14.1x. Average trailing P/E is 33x in the Healthcare industry in India. Valuation Update With 7 Day Price Move • Feb 20
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to ₹14.75, the stock trades at a trailing P/E ratio of 15x. Average trailing P/E is 38x in the Healthcare industry in India. Announcement • Feb 01
Dipna Pharmachem Limited Announces Resignation of Chinu Kalal from the Post of the Independent Director Dipna Pharmachem Limited informed that Ms. Chinu Kalal, has resigned from the post of the Independent Director w.e.f. 31st January, 2023. Reason for Resignation: Due to my pre-occupation elsewhere. Reported Earnings • Nov 18
First half 2023 earnings released First half 2023 results: EPS: ₹0.28. Net income: ₹3.32m (up ₹3.32m from 1H 2022). Valuation Update With 7 Day Price Move • Nov 11
Investor sentiment improved over the past week After last week's 16% share price gain to ₹22.70, the stock trades at a trailing P/E ratio of 23.3x. Average trailing P/E is 28x in the Healthcare industry in India. 